Jennifer Lum
Co-Founder & Managing Partner @ Biospring Partners
Boston, United States
Jennifer Lum is a Co-Founder and Managing Partner at Biospring Partners, a growth equity firm that invests in Life Sciences Technology. She is an accomplished entrepreneur and investor. She has cofounded several companies and has worked with many others from formation through to M&A.Jennifer is a Venture Capital Advisor at Harvard BusinessSchool and an Advisor at MIT’s Martin Trust Center for Entrepreneurship. She is also an Advisory Board member at The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School.Jennifer co-founded Forge.AI (acquired by FiscalNote) and Adelphic (acquired by Time). She was an early team member at Quattro Wireless (acquired by Apple), m-Qube (acquired by VeriSign) and WebHosting.com (acquired by AT&T).She has also held various roles as a management consultant with financial services and technology companies.Twitter: @lum
- Total investments:
- 24
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries Jennifer Lum invests in
Stages Jennifer Lum invests in
Countries Jennifer Lum invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $930k–$3M
- Pre-Seed
- $4M–$4.5M
- Series A
- $3M–$75M
Investment Focus
Industry
- Software 7 (29%)
- Artificial Intelligence 7 (29%)
- SaaS 6 (25%)
- Business Intelligence 6 (25%)
- Machine Learning 5 (21%)
Stage
- Seed 10 (42%)
- Series A 5 (21%)
- Pre-Seed 4 (17%)
- Angel 1 (4%)
- Series B 1 (4%)
Country
- United States 13 (54%)
- Canada 3 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Labviva is a digital marketplace for life science products that connects researchers with reagents, chemicals, and instrumentation suppliers. It leverages the scientific context as the organizing principle, connecting researchers with suppliers in an intuitive user-friendly platform while making it easy for suppliers to provide and manage thecontent for their products. Labviva's Inventory Management System (IMS) offers real-time inventory tracking, AI-driven purchase automation, and forecasting, enhancing operational efficiency and compliance. | $25M / Series B / Jan 13, 2025 | ||
| Building the world's first infringement detector. | $4.5M / Pre-Seed / Jun 27, 2023 | ||
Infringements
|
Monitor your patents and get instant alerts on potential infringements. | $4M / Pre-Seed / Jun 27, 2023 | |
| IPR-tested prior art search. The ultimate patent invalidation tool. | $4M / Pre-Seed / Jun 27, 2023 | ||
| Problems solved: - Multi-hop reasoning - Compound system data portability - Sub-second, multi-thousand data point synthesization - Multi-domain, multi-topic, multi-subject simultaneous analysis - Lossless recall - Zero hallucinations - And many, many more...Built. In Production. (Currently the reasoning engine powering Patented.ai to solve thehardest problems in litigation.) | Pre-Seed / Jun 27, 2023 | ||
| Labviva is a digital marketplace for life science products that connects researchers with reagents, chemicals, and instrumentation suppliers. It leverages the scientific context as the organizing principle, connecting researchers with suppliers in an intuitive user-friendly platform while making it easy for suppliers to provide and manage thecontent for their products. Labviva's Inventory Management System (IMS) offers real-time inventory tracking, AI-driven purchase automation, and forecasting, enhancing operational efficiency and compliance. | $20M / Series A / Mar 27, 2023 | ||
| ixlayer is an industry leader in the health-tech ecosystem, providing innovative solutions for enabling health systems, payors, biopharma, and health-focused companies to offer health testing in a virtual environment. The ixlayer platform delivers end-to-end solutions for the technical, security, regulatory, and user experience components ofcomplex health testing. As the industry shifts to remote and virtual care options, ixlayer is powering patient engagement and preventative health strategies through virtual health testing, at scale. The ixlayer solution can be added to existing patient engagement platforms and patient portals to enable real time health and wellness lab testing. Founded in 2018, ixlayer currently supports millions of patients and has launched hundreds of testing programs for large organizations, health systems and every level of the government. | $75M / Series A / Mar 11, 2021 | ||
| Uvaro's career success platform includes training, paid experience, advancement and ongoing coaching to ensure long-term career success. Our training program includes on-demand and live classes, our virtual internships let companies hire talent based on performance, our coaching and mentorship network drive ongoing career growth. Our averagestudent lands their new role in less than 17 days from graduation at more than 2x their previous income, and in their new roles achieve 50% more sales than their peers. | $1.6M / Seed / Sep 01, 2020 | ||
| Uvaro's career success platform includes training, paid experience, advancement, and ongoing coaching to ensure long-term career success. Their training program includes on-demand and live classes. Their virtual internships let companies hire talent based on performance. Their coaching and mentorship network drive ongoing career growth. | $1.6M / Seed / Sep 01, 2020 | ||
| Uvaro's career success platform includes training, paid experience, advancement, and ongoing coaching to ensure long-term career success. Their training program includes on-demand and live classes. Their virtual internships let companies hire talent based on performance. Their coaching and mentorship network drive ongoing career growth. | $3.5M / Seed / Jan 03, 2020 | ||
| See all 24 investments → | |||
Co-Investors
About Biospring Partners
Biospring Partners is a growth equity firm that invests in Life Sciences Technology. Biospring leverages its deep experience in life sciences and technology to support B2B services, tools, and enterprise software companies that are driving innovation across the life sciences industry and beyond.
Biospring Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Drew Pearson
Head of Portfolio Management
|
|||
|
Jennifer Lum
Co-Founder & Managing Partner
|
|||
Michelle Detwiler
Co-Founder and Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Jennifer Lum invest in?
Jennifer Lum invests primarily in Software, Artificial Intelligence and SaaS startups, most often at Seed and Series A stage. Most of the 24 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Jennifer Lum invest in?
Jennifer Lum typically joins rounds of $930k–$3M at Seed, $4M–$4.5M at Pre-Seed and $3M–$75M at Series A. These are whole funding-round sizes, not Jennifer Lum's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Jennifer Lum took part in.
How do I contact Jennifer Lum?
Public channels for Jennifer Lum include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jennifer Lum last invest?
The most recent investment recorded for Jennifer Lum closed in Jan 2025. Shizune tracks 24 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
